Share Price and Basic Stock Data
Last Updated: November 20, 2025, 8:55 pm
| PEG Ratio | -13.83 |
|---|
Analyst Insight & Comprehensive Analysis
AI Stock Ranker – Real-Time Fundamental Strength Score
Business Overview and Revenue Trends
Uravi Defence & Technology Ltd operates within the auto ancillary sector, specifically focusing on equipment lamps. The company reported a share price of ₹198 and a market capitalization of ₹225 Cr. For the fiscal year ending March 2025, total sales recorded were ₹43.63 Cr, while the trailing twelve months (TTM) sales were ₹43.51 Cr. Quarterly sales figures showed variability, with the highest sales of ₹11.40 Cr in March 2025, contrasting with the lowest of ₹10.02 Cr in December 2024 and June 2025. This indicates a degree of seasonality in revenue generation, with the operating profit margin (OPM) standing at 13.25% for the fiscal year 2025, suggesting that the company retains a reasonable portion of its revenue as profit. As the market environment evolves, the company’s ability to stabilize its revenue stream will be crucial for sustained growth. The significant fluctuations in quarterly sales point towards potential challenges in demand stability, which could impact overall performance.
Profitability and Efficiency Metrics
Uravi Defence & Technology Ltd reported a net profit of ₹2.55 Cr for the fiscal year ending March 2025, with a net profit margin of 4.46%. The operating profit for the same period was ₹5.78 Cr, leading to an operating profit margin of 13.25%. These figures illustrate a relatively healthy profitability profile, although the P/E ratio of 109 suggests that the stock may be overvalued compared to earnings. The company’s cash conversion cycle (CCC) stood at 511.92 days, indicating a significant duration for converting investments in inventory and receivables back into cash. This extended CCC may present liquidity challenges, potentially hampering operational efficiency. Furthermore, the interest coverage ratio (ICR) of 3.54x demonstrates a capacity to meet interest obligations, but the reliance on debt could pose risks if profitability does not improve. Overall, while profitability metrics appear stable, efficiency in managing working capital remains a concern.
Balance Sheet Strength and Financial Ratios
The balance sheet of Uravi Defence & Technology Ltd reveals a low long-term debt-to-equity ratio of 0.02, indicating minimal reliance on debt financing, which is a positive indicator for financial stability. Total debt to equity stands at 0.48, suggesting that while there is some leverage, it is not excessive. However, the absence of reported reserves and borrowings raises questions about the company’s financial flexibility. The current ratio of 1.90 indicates a solid liquidity position, allowing the company to cover short-term liabilities comfortably. The book value per share is ₹46.91, while the price-to-book value ratio is 7.47x, suggesting that the stock may be trading at a premium relative to its book value. This could indicate investor optimism, but it also raises the risk of valuation corrections. Overall, while the balance sheet appears robust, the lack of reserves could limit future growth opportunities and investments.
Shareholding Pattern and Investor Confidence
The shareholding structure of Uravi Defence & Technology Ltd reflects a notable concentration of ownership, with promoters holding 58.39% of the shares as of September 2025, a decline from 72.73% in earlier quarters. This reduction in promoter holding may raise concerns about their commitment to the company. Foreign institutional investors (FIIs) have increased their stake to 8.24%, reflecting growing interest from external investors. The public holding has also seen an increase to 33.38%, with the number of shareholders rising significantly to 3,133 by September 2025, suggesting a widening base of retail investors. This shift could be interpreted as a positive sign of increasing market confidence. However, the decline in promoter ownership could signal potential governance challenges or strategic shifts. Maintaining investor confidence will be critical as the company navigates its growth trajectory amidst these changes in ownership dynamics.
Outlook, Risks, and Final Insight
Looking ahead, Uravi Defence & Technology Ltd faces both opportunities and challenges. The company’s focus on the auto ancillary sector positions it well for growth, especially as the automotive market expands. However, the significant cash conversion cycle and fluctuating revenue trends pose risks to operational efficiency and liquidity. Additionally, the declining promoter stake could raise governance concerns, potentially affecting investor sentiment. On the positive side, the increasing presence of FIIs and a growing shareholder base could bolster market confidence. To capitalize on growth opportunities, the company must enhance its operational efficiency and stabilize its revenue streams while managing its debt levels prudently. Should the company address these risks effectively, it may strengthen its position in the market and improve profitability in the long run. Conversely, failure to manage these challenges could hinder its growth potential and affect shareholder returns.
Source: Getaka Fundamental Analysis | Generated using proprietary financial data.
Competitors of Uravi Defence & Technology Ltd
| Stock Name ⇩ | Market Cap ⇩ | Current Price ⇩ | High / Low ⇩ | Stock P/E ⇩ | Book Value ⇩ | Dividend Yield ⇩ | ROCE ⇩ | ROE ⇩ | Face Value ⇩ |
|---|---|---|---|---|---|---|---|---|---|
| Varroc Engineering Ltd | 10,228 Cr. | 669 | 675/365 | 52.8 | 110 | 0.15 % | 17.1 % | 7.37 % | 1.00 |
| Uravi Defence & Technology Ltd | 225 Cr. | 198 | 588/189 | 109 | 44.3 | 0.00 % | % | % | 10.0 |
| Lumax Industries Ltd | 4,726 Cr. | 5,054 | 5,358/1,960 | 31.7 | 873 | 0.69 % | 16.4 % | 19.3 % | 10.0 |
| Fiem Industries Ltd | 6,010 Cr. | 2,281 | 2,378/1,156 | 26.8 | 410 | 1.32 % | 27.8 % | 21.0 % | 10.0 |
| Industry Average | 5,297.25 Cr | 2,050.50 | 55.08 | 359.33 | 0.54% | 20.43% | 15.89% | 7.75 |
Quarterly Result
| Metric | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 |
|---|---|---|---|---|
| Sales | 11.12 | 10.02 | 11.40 | 10.02 |
| Expenses | 9.62 | 9.08 | 9.65 | 8.80 |
| Operating Profit | 1.50 | 0.94 | 1.75 | 1.22 |
| OPM % | 13.49% | 9.38% | 15.35% | 12.18% |
| Other Income | 0.07 | 0.37 | 0.33 | 0.40 |
| Interest | 0.57 | 0.40 | 0.39 | 0.39 |
| Depreciation | 0.55 | 0.55 | 0.51 | 0.52 |
| Profit before tax | 0.45 | 0.36 | 1.18 | 0.71 |
| Tax % | 33.33% | 25.00% | 31.36% | 25.35% |
| Net Profit | 0.35 | 0.71 | 0.93 | 0.53 |
| EPS in Rs | 0.32 | 0.65 | 0.76 | 0.39 |
Last Updated: August 20, 2025, 1:45 am
Below is a detailed analysis of the quarterly data for Uravi Defence & Technology Ltd based on the most recent figures (Jun 2025) and their trends compared to the previous period:
- For Sales, as of Jun 2025, the value is 10.02 Cr.. The value appears to be declining and may need further review. It has decreased from 11.40 Cr. (Mar 2025) to 10.02 Cr., marking a decrease of 1.38 Cr..
- For Expenses, as of Jun 2025, the value is 8.80 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 9.65 Cr. (Mar 2025) to 8.80 Cr., marking a decrease of 0.85 Cr..
- For Operating Profit, as of Jun 2025, the value is 1.22 Cr.. The value appears to be declining and may need further review. It has decreased from 1.75 Cr. (Mar 2025) to 1.22 Cr., marking a decrease of 0.53 Cr..
- For OPM %, as of Jun 2025, the value is 12.18%. The value appears to be declining and may need further review. It has decreased from 15.35% (Mar 2025) to 12.18%, marking a decrease of 3.17%.
- For Other Income, as of Jun 2025, the value is 0.40 Cr.. The value appears strong and on an upward trend. It has increased from 0.33 Cr. (Mar 2025) to 0.40 Cr., marking an increase of 0.07 Cr..
- For Interest, as of Jun 2025, the value is 0.39 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 0.39 Cr..
- For Depreciation, as of Jun 2025, the value is 0.52 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 0.51 Cr. (Mar 2025) to 0.52 Cr., marking an increase of 0.01 Cr..
- For Profit before tax, as of Jun 2025, the value is 0.71 Cr.. The value appears to be declining and may need further review. It has decreased from 1.18 Cr. (Mar 2025) to 0.71 Cr., marking a decrease of 0.47 Cr..
- For Tax %, as of Jun 2025, the value is 25.35%. The value appears to be improving (decreasing) as expected. It has decreased from 31.36% (Mar 2025) to 25.35%, marking a decrease of 6.01%.
- For Net Profit, as of Jun 2025, the value is 0.53 Cr.. The value appears to be declining and may need further review. It has decreased from 0.93 Cr. (Mar 2025) to 0.53 Cr., marking a decrease of 0.40 Cr..
- For EPS in Rs, as of Jun 2025, the value is 0.39. The value appears to be declining and may need further review. It has decreased from 0.76 (Mar 2025) to 0.39, marking a decrease of 0.37.
Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.
Profit & Loss - Annual Report
Last Updated: November 15, 2025, 4:13 am
| Metric | Mar 2025 | TTM |
|---|---|---|
| Sales | 43.63 | 43.51 |
| Expenses | 37.85 | 38.98 |
| Operating Profit | 5.78 | 4.53 |
| OPM % | 13.25% | 10.41% |
| Other Income | 0.97 | 1.37 |
| Interest | 1.91 | 1.56 |
| Depreciation | 2.05 | 2.06 |
| Profit before tax | 2.79 | 2.28 |
| Tax % | 30.11% | |
| Net Profit | 2.55 | 2.12 |
| EPS in Rs | 2.18 | 1.85 |
| Dividend Payout % | 0.00% |
YoY Net Profit Growth
| Year |
|---|
| YoY Net Profit Growth (%) |
| Change in YoY Net Profit Growth (%) |
No data available for trend analysis.
Growth
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | % |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | % |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | 49% |
| 3 Years: | 44% |
| 1 Year: | -25% |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| Last Year: | % |
Last Updated: September 5, 2025, 1:50 pm
No data available for the Balance Sheet data table.
Cash Flow
| Month | Mar 2025 |
|---|---|
Financial Efficiency Indicators
| Month | Mar 2025 |
|---|---|
| Debtor Days | 119.97 |
| Inventory Days | 453.33 |
| Days Payable | 61.37 |
| Cash Conversion Cycle | 511.92 |
| Working Capital Days | 122.81 |
| ROCE % |
This stock is not held by any mutual fund.
Key Financial Ratios
| Month | Mar 25 |
|---|---|
| FaceValue | 10.00 |
| Basic EPS (Rs.) | 2.31 |
| Diluted EPS (Rs.) | 2.25 |
| Cash EPS (Rs.) | 3.55 |
| Book Value[Excl.RevalReserv]/Share (Rs.) | 46.91 |
| Book Value[Incl.RevalReserv]/Share (Rs.) | 46.91 |
| Revenue From Operations / Share (Rs.) | 38.75 |
| PBDIT / Share (Rs.) | 5.99 |
| PBIT / Share (Rs.) | 4.17 |
| PBT / Share (Rs.) | 2.48 |
| Net Profit / Share (Rs.) | 1.73 |
| NP After MI And SOA / Share (Rs.) | 2.26 |
| PBDIT Margin (%) | 15.46 |
| PBIT Margin (%) | 10.76 |
| PBT Margin (%) | 6.39 |
| Net Profit Margin (%) | 4.46 |
| NP After MI And SOA Margin (%) | 5.83 |
| Return on Networth / Equity (%) | 4.81 |
| Return on Capital Employeed (%) | 8.54 |
| Return On Assets (%) | 2.86 |
| Long Term Debt / Equity (X) | 0.02 |
| Total Debt / Equity (X) | 0.48 |
| Current Ratio (X) | 1.90 |
| Quick Ratio (X) | 1.11 |
| Interest Coverage Ratio (X) | 3.54 |
| Interest Coverage Ratio (Post Tax) (X) | 2.02 |
| Enterprise Value (Cr.) | 404.69 |
| EV / Net Operating Revenue (X) | 9.28 |
| EV / EBITDA (X) | 59.98 |
| MarketCap / Net Operating Revenue (X) | 9.05 |
| Price / BV (X) | 7.47 |
| Price / Net Operating Revenue (X) | 9.05 |
| EarningsYield | 0.01 |
After reviewing the key financial ratios for Uravi Defence & Technology Ltd, here is a detailed analysis based on the latest available data and recent trends:
- For FaceValue, as of Mar 25, the value is 10.00. This value is within the healthy range. No previous period data is available for comparison.
- For Basic EPS (Rs.), as of Mar 25, the value is 2.31. This value is below the healthy minimum of 5. No previous period data is available for comparison.
- For Diluted EPS (Rs.), as of Mar 25, the value is 2.25. This value is below the healthy minimum of 5. No previous period data is available for comparison.
- For Cash EPS (Rs.), as of Mar 25, the value is 3.55. This value is within the healthy range. No previous period data is available for comparison.
- For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 46.91. No previous period data is available for comparison.
- For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 46.91. No previous period data is available for comparison.
- For Revenue From Operations / Share (Rs.), as of Mar 25, the value is 38.75. No previous period data is available for comparison.
- For PBDIT / Share (Rs.), as of Mar 25, the value is 5.99. This value is within the healthy range. No previous period data is available for comparison.
- For PBIT / Share (Rs.), as of Mar 25, the value is 4.17. This value is within the healthy range. No previous period data is available for comparison.
- For PBT / Share (Rs.), as of Mar 25, the value is 2.48. This value is within the healthy range. No previous period data is available for comparison.
- For Net Profit / Share (Rs.), as of Mar 25, the value is 1.73. This value is below the healthy minimum of 2. No previous period data is available for comparison.
- For NP After MI And SOA / Share (Rs.), as of Mar 25, the value is 2.26. This value is within the healthy range. No previous period data is available for comparison.
- For PBDIT Margin (%), as of Mar 25, the value is 15.46. This value is within the healthy range. No previous period data is available for comparison.
- For PBIT Margin (%), as of Mar 25, the value is 10.76. This value is within the healthy range. No previous period data is available for comparison.
- For PBT Margin (%), as of Mar 25, the value is 6.39. This value is below the healthy minimum of 10. No previous period data is available for comparison.
- For Net Profit Margin (%), as of Mar 25, the value is 4.46. This value is below the healthy minimum of 5. No previous period data is available for comparison.
- For NP After MI And SOA Margin (%), as of Mar 25, the value is 5.83. This value is below the healthy minimum of 8. No previous period data is available for comparison.
- For Return on Networth / Equity (%), as of Mar 25, the value is 4.81. This value is below the healthy minimum of 15. No previous period data is available for comparison.
- For Return on Capital Employeed (%), as of Mar 25, the value is 8.54. This value is below the healthy minimum of 10. No previous period data is available for comparison.
- For Return On Assets (%), as of Mar 25, the value is 2.86. This value is below the healthy minimum of 5. No previous period data is available for comparison.
- For Long Term Debt / Equity (X), as of Mar 25, the value is 0.02. This value is below the healthy minimum of 0.2. No previous period data is available for comparison.
- For Total Debt / Equity (X), as of Mar 25, the value is 0.48. This value is within the healthy range. No previous period data is available for comparison.
- For Current Ratio (X), as of Mar 25, the value is 1.90. This value is within the healthy range. No previous period data is available for comparison.
- For Quick Ratio (X), as of Mar 25, the value is 1.11. This value is within the healthy range. No previous period data is available for comparison.
- For Interest Coverage Ratio (X), as of Mar 25, the value is 3.54. This value is within the healthy range. No previous period data is available for comparison.
- For Interest Coverage Ratio (Post Tax) (X), as of Mar 25, the value is 2.02. This value is below the healthy minimum of 3. No previous period data is available for comparison.
- For Enterprise Value (Cr.), as of Mar 25, the value is 404.69. No previous period data is available for comparison.
- For EV / Net Operating Revenue (X), as of Mar 25, the value is 9.28. This value exceeds the healthy maximum of 3. No previous period data is available for comparison.
- For EV / EBITDA (X), as of Mar 25, the value is 59.98. This value exceeds the healthy maximum of 15. No previous period data is available for comparison.
- For MarketCap / Net Operating Revenue (X), as of Mar 25, the value is 9.05. This value exceeds the healthy maximum of 3. No previous period data is available for comparison.
- For Price / BV (X), as of Mar 25, the value is 7.47. This value exceeds the healthy maximum of 3. No previous period data is available for comparison.
- For Price / Net Operating Revenue (X), as of Mar 25, the value is 9.05. This value exceeds the healthy maximum of 3. No previous period data is available for comparison.
- For EarningsYield, as of Mar 25, the value is 0.01. This value is below the healthy minimum of 5. No previous period data is available for comparison.
Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.
Strength and Weakness
Unable to fetch valid data for stock valuation.Stock Analysis
- Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in Uravi Defence & Technology Ltd:
- Net Profit Margin: 4.46%
- Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
- ROCE: 8.54% (Industry Average ROCE: 20.43%)
- ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
- ROE%: 4.81% (Industry Average ROE: 15.89%)
- ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
- Interest Coverage Ratio (Post Tax): 2.02
- Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
- Quick Ratio: 1.11
- Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
- Stock P/E: 109 (Industry average Stock P/E: 55.08)
- Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
- Total Debt / Equity: 0.48
- Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
Stock Rating: - Net Profit Margin: 4.46%
About the Company - Qualitative Analysis
| INDUSTRY | ADDRESS | CONTACT |
|---|---|---|
| Auto Ancl - Equipment Lamp | Shop No. 329 Avior, Nirmal Galaxy, Mumbai Maharashtra 400080 | info@uravilamps.com http://www.uravilamps.com |
| Management | |
|---|---|
| Name | Position Held |
| Mr. Niraj Damji Gada | Managing Director & CEO |
| Mr. Kaushik Damji Gada | WholeTime Director & CFO |
| Mr. Brijesh Aggarwal | Non Executive Director |
| Ms. Shreya Ramkrishnan | Ind. Non-Executive Director |
| Mr. Sreedhar Ramachandran Ayalur | Ind. Non-Executive Director |
| Mr. Niken Shah | Ind. Non-Executive Director |